Saturday 17 October 2026
Export ZTS’s income statement to Excel — free account
Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
79.20
0.78
+0.99%
Follow ZTS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.82 | 19.57 | 20.87 | 24.63 |
+8 more quarters Free account |
P/S ratio |
3.15 | 5.24 | 5.89 | 6.90 | |
P/FCF ratio |
12.90 | 22.21 | 24.44 | 28.93 | |
P/Operating CF |
45.81 | 124.43 | 62.48 | 72.73 | |
P/B ratio |
9.53 | 15.43 | 16.34 | 12.01 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 40.66 | |
EV/Sales |
4.07 | 6.12 | 6.73 | 7.58 | |
EV/EBITDA |
9.64 | 14.37 | 15.66 | 17.75 | |
EV/Operating CF |
13.64 | 20.91 | 21.95 | 24.40 | |
EV/FCF |
16.64 | 25.97 | 27.92 | 31.76 | |
Quick Ratio |
1.58 | 1.68 | 1.78 | 2.01 | |
Current Ratio |
3.08 | 3.15 | 3.12 | 3.64 | |
Net Debt/EBITDA |
7.05 | 7.57 | 6.82 | 4.67 | |
Debt/Assets |
60.01% | 59.69% | 58.37% | 46.63% | |
Debt/Equity |
2.87 | 2.80 | 2.65 | 1.31 | |
Asset Turnover |
0.64 | 0.65 | 0.64 | 0.64 | |
Operating CF/Net income |
0.95 | 0.67 | 1.43 | 1.24 | |
Capex/Depreciation |
(0.97) | (0.84) | (1.34) | (1.10) | |
Interest Coverage |
15.20 | 13.23 | 14.82 | 16.29 | |
Research and Development Expense of Revenue |
7.01% | 7.96% | 8.35% | 7.08% | |
Selling, General and Administrative Expense of Revenue |
23.99% | 25.99% | 25.51% | 24.13% | |
Intangible Assets out of Total Assets |
0.24 | 0.25 | 0.24 | 0.25 | |
Share Based Compensation of Revenue |
1.05% | 1.11% | 0.92% | 0.92% | |
Graham Net Nets |
(0.19) | (0.11) | (0.09) | (0.05) | |
Graham Number |
32.11 | 32.26 | 32.32 | 40.36 | |
Earnings Yield |
8.46% | 5.11% | 4.79% | 4.06% | |
Free Cash Flow Yield |
7.75% | 4.50% | 4.09% | 3.46% | |
Revenue per Share |
5.91 | 5.36 | 5.40 | 5.42 | |
Operating CF per Share |
1.57 | 0.95 | 2.01 | 2.01 | |
Capex per Share |
(0.28) | (0.24) | (0.37) | (0.30) | |
Free Cash Flow per Share |
1.29 | 0.71 | 1.65 | 1.71 | |
Cash per Share |
4.01 | 4.60 | 5.52 | 4.71 | |
Shareholders Equity per Share |
7.54 | 7.66 | 7.70 | 12.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.54 | 7.66 | 7.70 | 12.19 | |
Free Cash Flow |
539.00 | 301.00 | 731.00 | 756.00 | |
Working Capital |
4,295.00 | 4,421.00 | 4,600.00 | 4,776.00 | |
Capital Expenditures |
(116.00) | (100.00) | (162.00) | (135.00) | |
Net Current Asset Value |
(5,573.00) | (5,447.00) | (5,302.00) | (3,178.00) | |
EV/EBIT |
10.95 | 16.32 | 17.79 | 20.21 | |
Capex to Sales |
0.05 | 0.04 | 0.07 | 0.06 | |
Price to Operating Income |
9.10 | 14.92 | 16.61 | 19.61 | |
| Other line items | |||||
Average Receivables |
1,555.50 | 1,433.50 | 1,362.50 | 1,476.00 | |
Average Payables |
480.00 | 463.50 | 439.00 | 407.00 | |
Average Inventory |
2,506.50 | 2,457.50 | 2,385.00 | 2,440.50 | |
Average Assets |
14,778.00 | 14,626.00 | 14,863.50 | 14,758.00 | |
Average Common Equity |
4,062.50 | 3,944.00 | 4,092.50 | 5,316.00 |
Columns are period end dates